Sree Kanth Sivan
Overview
Explore the profile of Sree Kanth Sivan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Desai N, Khasiya A, Jadeja D, Monapara J, Jethawa A, Dave B, et al.
ACS Omega
. 2023 Oct;
8(41):37781-37797.
PMID: 37867649
Multidrug-resistant fungal infections have become much more common in recent years, especially in immune-compromised patients. Therefore, researchers and pharmaceutical professionals have focused on the development of novel antifungal agents that...
2.
Computational design, synthesis and evaluation of new sulphonamide derivatives targeting HIV-1 gp120
Vangala R, Sivan S, Peddi S, Manga V
J Comput Aided Mol Des
. 2019 Dec;
34(1):39-54.
PMID: 31792886
Attachment of envelope glycoprotein gp120 to the host cell receptor CD4 is the first step during the human immunodeficiency virus-1 (HIV-1) entry into the host cells that makes it a...
3.
Bathula R, Lanka G, Muddagoni N, Dasari M, Nakkala S, Bhargavi M, et al.
J Biomol Struct Dyn
. 2019 Jun;
38(8):2314-2325.
PMID: 31204611
Genomic instability is a trademark of cancer evolution, there is still a wide necessity to discover safe and effective anti-cancer drugs. Aurora kinase-C protein is a member of the Aurora...
4.
Itteboina R, Ballu S, Sivan S, Manga V
J Recept Signal Transduct Res
. 2019 May;
38(5-6):462-474.
PMID: 31038024
A therapeutic rationale is proposed by selectively targeting tyrosine kinase 2 (TYK 2) to obtain potent TYK 2 inhibitors by molecular modeling studies. In the present study, we have taken...
5.
Munnaluri R, Peddi S, Sivan S, Manga V
Comput Biol Chem
. 2018 Dec;
78:81-94.
PMID: 30500556
The fight against tuberculosis (TB) is a time immemorial one and the emergence of new drug resistant strains of Mycobacterium tuberculosis keeps throwing new challenges to the scientific community immersed...
6.
Ballu S, Itteboina R, Sivan S, Manga V
Comput Biol Chem
. 2018 Feb;
73:95-104.
PMID: 29475176
Staphylococcus aureus is a gram positive bacterium. It is the leading cause of skin and respiratory infections, osteomyelitis, Ritter's disease, endocarditis, and bacteraemia in the developed world. We employed combined...
7.
Akula S, Kamasani S, Sivan S, Manga V, Vudem D, Kancha R
J Thorac Oncol
. 2018 Jan;
13(5):721-726.
PMID: 29369805
Introduction: A significant proportion of patients with lung cancer carry mutations in the EGFR kinase domain. The presence of a deletion mutation in exon 19 or L858R point mutation in...
8.
Ballu S, Itteboina R, Sivan S, Manga V
J Recept Signal Transduct Res
. 2018 Jan;
38(1):61-70.
PMID: 29369011
Filamentous temperature-sensitive protein Z (FtsZ) is a protein encoded by the FtsZ gene that assembles into a Z-ring at the future site of the septum of bacterial cell division. Structurally,...
9.
Itteboina R, Ballu S, Sivan S, Manga V
J Recept Signal Transduct Res
. 2017 May;
37(5):453-469.
PMID: 28537140
Janus kinase 1 (JAK 1) belongs to the JAK family of intracellular nonreceptor tyrosine kinase. JAK-signal transducer and activator of transcription (JAK-STAT) pathway mediate signaling by cytokines, which control survival,...
10.
Kamasani S, Akula S, Sivan S, Manga V, Duyster J, Vudem D, et al.
Tumour Biol
. 2017 May;
39(5):1010428317701643.
PMID: 28475010
The ABL kinase inhibitor imatinib has been used as front-line therapy for Philadelphia-positive chronic myeloid leukemia. However, a significant proportion of imatinib-treated patients relapse due to occurrence of mutations in...